Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (NCT07168356) titled 'A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease' on Sept. 10.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: GlaxoSmithKline

Condition: Hepatitis B

Intervention: Drug: Bepirovirsen

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: September 16, 2025

Target Sample Size: 32

To know more, visit https://clinicaltrials.gov/study/NCT07168356

Disclaimer: Curated by HT Syndication....